Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
CA 2459161 A1 · Owner: Children'S Hospital Medical Center · Inventors: Snyder, Gretchen; Greengard, Paul; Repaske, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1 B (PDE1B) in intracellular signaling pathways including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules including, but not limited , to, DARPP-32 and GluR1 AMPA receptor via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder including but not limited , to a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 3, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 3, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 3, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.